AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age≥18 years
✓. Patient with NSTE-ACS or CCS with either symptoms and/or ischemia on non-invasive or invasive testing (i.e. FFR/iFR, CMR, SPECT, PET-CT or stress-echo)
✓. The patient must be able to understand and provide written informed consent and comply with all study procedures
✓. Life expectancy of \> 2 years
✓. One or more trial target vessel (LAD, CX or RCA, or of their branches) with:
✓. Stenosis of ≥70% or
✓. Stenosis ≥50% and \<70% (visually assessed) with evidence of ischemia by positive stress test, or FFR ≤0.80, or iFR \<0.90 or IVUS minimum lumen area ≤4.0 mm2
✓. The target vessel/target lesion matches at least one of the following criteria
Exclusion criteria
✕. STEMI or cardiogenic shock related to an acute MI within 2 days prior to the index PCI
✕. Pregnancy or nursing declarations (As per country specific guideline) (a negative pregnancy test is required of women with child-bearing potential within 7 days prior to enrollment)
✕. LVEF\<30%
✕. Known contraindication or hypersensitivity to any limus family drugs, paclitaxel, or to medications such as heparin, aspirin, clopidogrel, ticlopidine, prasugrel and ticagrelor or any component of the devices.